Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 Grant US-11952422-B2 United States of America 09 Apr 2024
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable… Grant US-11859010-B2 United States of America 02 Jan 2024
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain Grant US-11851476-B2 United States of America 26 Dec 2023
Antigen-binding molecule containing modified antibody variable region Grant US-11739149-B2 United States of America 29 Aug 2023
CD137- and DLL3-targeting multispecific antigen-binding molecules Grant US-11718672-B2 United States of America 08 Aug 2023
Combination therapy using T cell redirection antigen binding molecule against cell having… Grant US-11660340-B2 United States of America 30 May 2023
Method for promoting efficiency of purification of Fc region-containing polypeptide Grant US-11649262-B2 United States of America 16 May 2023
Method for enhancing humoral immune response Grant US-11649293-B2 United States of America 16 May 2023
Prevention of adverse effects caused by CD3 specific binding domains Grant US-11633408-B2 United States of America 25 Apr 2023
T cell-redirected antigen-binding molecule for cells having immunosuppression function Grant US-11505605-B2 United States of America 22 Nov 2022
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable… Grant US-11472889-B2 United States of America 18 Oct 2022
CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof Grant US-11274151-B2 United States of America 15 Mar 2022
ANTI-T CELL ANTIGEN-BINDING MOLECULE FOR USE IN COMBINATION WITH ANGIOGENESIS INHIBITOR Application WO-2021256555-A1 World Intellectual Property Organisation (WIPO) 23 Dec 2021
Methods for producing polypeptides by regulating polypeptide association Grant US-11168344-B2 United States of America 09 Nov 2021
Multispecific antibodies, multispecific activatable antibodies and methods of using the… Grant US-11161906-B2 United States of America 02 Nov 2021
Library of antigen-binding molecules including modified antibody variable region Grant US-11154615-B2 United States of America 26 Oct 2021
Method for producing polypeptide hetero-oligomer Grant US-11142587-B2 United States of America 12 Oct 2021
Method for producing polypeptide heteromultimer Grant US-11124576-B2 United States of America 21 Sep 2021
Methods of modifying antibodies for purification of bispecific antibodies Grant US-10934344-B2 United States of America 02 Mar 2021
THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS Application EP-3736293-A1 European Patent Office 11 Nov 2020
THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS Grant EP-2956483-B1 European Patent Office 27 May 2020
Combination of the application of antibodies for immunostimulation together with… Grant US-10576149-B2 United States of America 03 Mar 2020
METHOD FOR THE TREATMENT OF CANCER USING BISPECIFIC ANTIBODIES AGAINST CD3 AND DLL3 Application EA-034182-B1 Eurasian Patent Organisation 15 Jan 2020
Anti-DLL3 antibody drug conjugates for treating cancer Grant US-10137204-B2 United States of America 27 Nov 2018
Prevention of adverse effects caused by CD3 specific binding domains Application US-10130638-B2 United States of America 20 Nov 2018
Combination of the application of antibodies for immunostimulation together with… Grant US-10071158-B2 United States of America 11 Sep 2018
Methods for producing polypeptides by regulating polypeptide association Grant US-10011858-B2 United States of America 03 Jul 2018
Therapeutic and diagnostic target for cancer comprising DLL3 binding reagents Grant AU-2014217611-B2 Australia 17 May 2018
Method of modifying isoelectric point of antibody via amino acid substitution in CDR Grant US-9828429-B2 United States of America 28 Nov 2017
Methods of modifying antibodies for purification of bispecific antibodies Grant US-9670269-B2 United States of America 06 Jun 2017
Methods of making DLL3 antibody drug conjugates Grant US-9358304-B1 United States of America 07 Jun 2016
Kits containing DLL3 antibody drug conjugates Grant US-9352051-B1 United States of America 31 May 2016
Methods of delivering DLL3 antibody drug conjugates Grant US-9345784-B1 United States of America 24 May 2016
Anti-DLL3 antibody drug conjugates and methods of use Grant US-9155803-B1 United States of America 13 Oct 2015
Anti-DLL3 antibody drug conjugates and methods of use Grant US-9133271-B1 United States of America 15 Sep 2015
Anti-DLL3 antibody drug conjugates for treating cancer Grant US-9107961-B2 United States of America 18 Aug 2015
Anti-DLL3 antibody drug conjugates and methods of use Grant US-9089616-B2 United States of America 28 Jul 2015
Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies Grant US-9090683-B2 United States of America 28 Jul 2015
METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE Application WO-2014116846-A3 World Intellectual Property Organisation (WIPO) 23 Oct 2014
RECOMBINANT BISPECIFIC ANTIBODY THAT BINDS TO THE CD133 ANTIGEN ON TUMOR CELLS AND TO THE… Application WO-2014128185-A1 World Intellectual Property Organisation (WIPO) 28 Aug 2014
Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the… Application EP-2769989-A1 European Patent Office 27 Aug 2014
THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS Application WO-2014125273-A1 World Intellectual Property Organisation (WIPO) 21 Aug 2014
Combination of the application of antibodies for immunostimulation together with… Grant US-8709421-B2 United States of America 29 Apr 2014
TREATMENT OF LUNG CANCER WITH A PARP INHIBITOR IN COMBINATION WITH A GROWTH FACTOR… Application EP-2393364-A4 European Patent Office 13 Mar 2013
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT Application WO-2012073985-A1 World Intellectual Property Organisation (WIPO) 07 Jun 2012
TREATMENT OF LUNG CANCER WITH A PARP INHIBITOR IN COMBINATION WITH A GROWTH FACTOR… Application EP-2393364-A1 European Patent Office 14 Dec 2011